- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00741767
The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (AQuOS-COPD)
The Impact of Salmeterol-Fluticasone on Sleep in Patients With COPD (Advair and Quality of Sleep in COPD)
Study Overview
Status
Intervention / Treatment
Detailed Description
Chronic obstructive pulmonary disease (COPD) is a common and clinically important disease characterized by chronic, irreversible airflow obstruction. Poor sleep quality and insomnia are well described phenomena in patients with COPD. Several studies suggest sleep disturbance adversely affects quality of life and may worsen daytime pulmonary function in COPD patients. Improving sleep quality in patients with COPD, therefore, may not only improve health quality, but also attenuate the decline in daytime pulmonary function.
Previous studies investigating the effects of inhaled bronchodilators on sleep quality in COPD have shown conflicting results. These conflicting data prompted us to perform a retrospective study on patients with COPD and co-existing sleep apnea (OSA) investigating the effects of mechanical lung function impairment and lung hyperinflation on sleep. Our study found a significant correlation between increased lung hyperinflation and reduced sleep efficiency (a measure of sleep quality), and this relationship was preserved in a multivariable regression model.
We hypothesize that Advair Diskus improves sleep quality by reducing lung hyperinflation in COPD. To test this hypothesis, we propose a double-blinded, placebo controlled cross-over study of Advair Diskus in patients with COPD and lung hyperinflation.
It was mutually decided by the sponsor and principal investigator to terminate the study early due to study subject enrollment difficulties.
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 40 years of age
- BMI<30
- Former smokers with ≥ 10 pack-year history
- Diagnosis of COPD, as defined by the American Thoracic Society (FEV1/FVC < 70 with history of exposure to noxious particles or gases)
- Moderate to severe COPD as defined as an FEV1 ≤ 80% predicted
- Functional residual capacity > 120% or inspiratory capacity < 80% predicted on pulmonary function testing
Poor subjective sleep quality: All subjects included must answer "yes" to at least one of the following questions:
- Do you have trouble falling asleep?
- Do you have trouble staying asleep?
- Do you not get enough sleep?
- Do you wake up too early and not be able to get back to sleep?
- Do you fall asleep during the day?
Exclusion Criteria:
- Conditions that in the judgment of the investigator would interfere with subject participation in the study
- BMI > 30
- History of or physician diagnosed pulmonary disorder other than COPD
- History of significant obstructive sleep disordered breathing (apnea-hypopnea index > 15) or presence of central sleep apnea
- History of narcolepsy, primary hypersomnia, periodic limb movement disorder, or parasomnia
- History of psychiatric illness
- Presence of decompensated heart failure
- Use of prednisone, antibiotic therapy, or new medication for COPD in the previous 3 months
- Use of any sleep aids
- History of ≥ 1 COPD exacerbation (defined as requiring oral corticosteroids and/or antibiotics as either an outpatient or inpatient)
- Known allergy or significant adverse reactions to inhaled beta2-agonists and inhaled corticosteroids (not including thrush and dysphonia)
- Pregnancy or lactating
- Inability or unwillingness to provide informed consent
- Inability to effectively use study medication or perform baseline measurements
- Inability to be contacted by phone
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Salmeterol-fluticasone
Patients randomized to receive salmeterol-fluticasone 250/50 twice daily for 4 weeks.
Patients will cross-over and receive placebo medication for 4 weeks later in the study.
|
250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
Other Names:
|
Other: Placebo
Patients randomized to receive placebo medication twice daily for 4 weeks.
Patients will cross-over and receive study medication later in the study.
|
250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in subjective measures of sleep quality
Time Frame: 16 weeks
|
16 weeks
|
Changes in objective measures of sleep and daytime cognitive function
Time Frame: 16 weeks
|
16 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Changes in lung hyperinflation and systemic inflammation
Time Frame: 16 weeks
|
16 weeks
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Ravi Kalhan, MD, MS, Northwestern University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Nervous System Diseases
- Respiratory Tract Diseases
- Neurologic Manifestations
- Lung Diseases
- Lung Diseases, Obstructive
- Pulmonary Disease, Chronic Obstructive
- Sleep Wake Disorders
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Adrenergic Agonists
- Dermatologic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Anti-Allergic Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Sympathomimetics
- Fluticasone
- Salmeterol Xinafoate
- Fluticasone-Salmeterol Drug Combination
Other Study ID Numbers
- 3582
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Obstructive Pulmonary Disease
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on salmeterol-fluticasone
-
Arthur F Gelb MDCompleted
-
University of DundeeCompleted
-
Neovii BiotechFresenius Biotech North AmericaCompletedOvarian CancerUnited States
-
Novartis PharmaceuticalsCompletedChronic Obstructive Pulmonary DiseaseChina, Argentina, Taiwan, Chile
-
GlaxoSmithKlineWithdrawnPulmonary Disease, Chronic Obstructive
-
Respirent Pharmaceuticals Co Ltd.Becro Ltd.Completed
-
Johns Hopkins UniversityGlaxoSmithKline; American Lung AssociationCompleted
-
GlaxoSmithKlineCompletedAsthmaUnited States, Argentina, Philippines, Canada, Brazil
-
GlaxoSmithKlineCompleted
-
University of MiamiGlaxoSmithKlineCompleted